E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028130 |
E.1.2 | Term | Mucositis oral |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the pharmacokinetic profile and biological activity on buccal mucosae of palifermin administered at the dose of 120 μg/kg IV in a cohort of at least 16 (3 palifermin : 1 placebo) locally advanced HNC subjects receiving RT with concurrent CT as adjuvant treatment for their disease (post-operative setting).
To evaluate the safety and tolerability of palifermin when administered at the dose of 120 μg/kg weekly for up to 8 consecutive weeks to patients with locally advanced HNC receiving RT with concurrent CT as adjuvant treatment for their disease (post-operative setting). |
|
E.2.2 | Secondary objectives of the trial |
To assess the preliminary efficacy of 120 μg/kg palifermin in reducing the incidence and duration of severe oral mucositis (OM) (Adapted RTOG/EORTC grade ≥3)
To assess the preliminary efficacy of palifermin on the clinical sequelae of OM and Patient-reported mouth and throat soreness (MTS)
To evaluate long-term effects of palifermin on disease outcome and survival. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed informed consent
• ≥18 years of age
• History of newly diagnosed histologically confirmed squamous cell carcinoma (AJCC Stage II, III, IVA, or IVB) involving either the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx, post surgical resection (R0, R1) and candidates for adjuvant RT/CT
• High-risk subject defined by presence of at least one of the following: R1 resection margins; T3 or T4 tumor stage; 3 or more positive lymph node metastases; <3 lymph node metastases with extracapsular extension of the disease
• Scheduled to receive adjuvant concurrent chemoradiation treatment within 12 weeks of surgery
• Radiation treatment field to receive planned dose of at least 50Gy to areas of the oral cavity/oropharynx mucosa that can be visualized (Subjects with larynx or hypopharynx tumors are eligible only if the radiation oncologist anticipates a significant part of the oral mucosa to receive a total dose of 50Gy or
more.
• Karnofsky performance status ≥ 70
• Planned interval < 6 calendar days between randomization and the first dose of RT
• Baseline laboratory assessments:
− Hemoglobin (Hgb) ≥ 10g/dL
− White blood count (WBC) > 3.5 x 109/L or absolute neutrophil count (ANC) > 1.5 x 109/L
− Platelet count ≥ 100 x 109/L
− Serum bilirubin ≤ 1.5 x institutional upper limits of normal (ULN)
− Serum creatinine ≤ 2.0 mg/dL; Subjects with a serum creatinine ≥ 1.4 mg/dL and ≤ 2.0 mg/dL need to demonstrate a 24-hr urinary creatinine clearance ≥ 50 mL/min
− Females of childbearing potential: negative serum or urine pregnancy test |
|
E.4 | Principal exclusion criteria |
• Tumors of the lips, paranasal sinuses, salivary glands, or of unknown primary tumors
• Metastatic disease (M1) / Stage IV C
• Presence or history of any other primary malignancy
• History of pancreatitis
• Prior radiotherapy to the site of disease
• Prior chemotherapy
• Other investigational procedures
• Thirty days or less since receiving an investigational product or device in another clinical trial. Current enrollment in another clinical trial is not permitted unless the sole purpose of the trial is for long-term follow-up/survival data.
• Pregnant or breast-feeding women permitted unless the sole purpose of the trial is for long-term follow-up/survival data.
• Refusal to use adequate contraceptive devices during treatment phase
• Known sensitivity to any of the products administered during dosing, including E coli-derived products
• Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
• Previous treatment on this study or with other keratinocyte growth factors
• Compromised ability of the subject to give written informed consent and/or to comply with study procedures
• Refusal to give written informed consent to participate in this study and to sign the hospital information release form
• Unwilling or unable to complete the patient-reported outcome questionnaires
• Psychological, social, familial, or geographical reasons that would prevent regular follow-up. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacokinetic endpoints:
PK endpoints will include, but are not limited to:
• systemic clearance (CL)
• volume of distribution at steady state (Vss)
• estimated initial concentration (C0)
• area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC(0-t)) and to infinity (AUC(0-∞))
• terminal half-life (t1/2,z)
• mean residence time (MRT)
Pharmacodynamics Endpoints
The primary PD endpoint will be cell proliferation assayed by staining for cell cycle proliferation marker Ki67.
Safety and Efficacy Endpoints:
Proportion of subjects with protocol-specific limiting toxicity
• Incidence of adverse events and laboratory abnormalities using the CTCAE v.3.0 toxicity scales
• Incidence (%) and duration (days) of severe oral mucositis (Adapted RTOG/EORTC) grade ≥3
• Time (days) to onset of severe oral mucositis (Adapted RTOG/EORTC grade ≥3)
• Incidence (%) and duration (days) of oral mucositis (Adapted RTOG/EORTC grade ≥2)
• Time (days) to onset of oral mucositis (Adapted RTOG/EORTC grade ≥2)
• Opioid analgesics use (incidence, total dose of morphine equivalents)
• Incidence of unplanned RT and CT breaks
• Changes in performance status and body weight (kg)
Long-term Safety Endpoints
• Incidence of second primary tumors
• Incidence of other malignancies
• Progression-free survival (PFS)
• Overall survival (OS)
• Incidence of leukoplakia |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Evaluations of oral mucosal surfaces (mucositis assessments) occur daily (weekdays) throughout CT/RT, then 2 times weekly thereafter until mucositis has resolved to Grade ≤ 2, once mucositis has resolved to Grade ≤ 2 subjects will return to the clinic for mucositis assessments once a week until mucositis has resolved to grade ≤ 1. If OM does not resolve to Grade ≤ 1 by week 15, subjects should continue to have a once weekly assessment until resolution to Grade ≤ 1 but not beyond week 24 / month 6. |
|
E.5.2 | Secondary end point(s) |
Exploratory endpoints
Evaluation of potential biomarkers with respect to chemo/radiotherapy-induced oral mucositis and treatment regimen
Evaluation of genetic variation as related to presence of mucositis and patient response to treatment |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Evaluations of oral mucosal surfaces (mucositis assessments) occur daily (weekdays) throughout CT/RT, then 2 times weekly thereafter until mucositis has resolved to Grade ≤ 2, once mucositis has resolved to Grade ≤ 2 subjects will return to the clinic for mucositis assessments once a week until mucositis has resolved to grade ≤ 1. If OM does not resolve to Grade ≤ 1 by week 15, subjects should continue to have a once weekly assessment until resolution to Grade ≤ 1 but not beyond week 24 / month 6. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
All subjects will be followed for up to 10 years from the last subject randomized or until death or loss to follow-up. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |